These findings underscore the dual role of hypoxia and HIF-1α in shaping the tumor’s resistance to oncolytic virotherapy and highlight potential strategies, such as HIF-1α inhibition, to overcome these barriers and enhance the therapeutic efficacy of VSV. The gene discussed is HIF1A; the disease is neoplasm.